Solid Biosciences Announces FDA IND and Health Canada CTA Approval for First-in-Class Cardiac Gene Therapy To Treat Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)
Solid Biosciences, which acquired UF startup AavantiBio, announced FDA and Health Canada approval to begin clinical trials of SGT-501, a gene therapy targeting CPVT, a severe heart rhythm disorder caused by RYR2 mutations.
TuHURA Biosciences Initiates Its Phase 3 Accelerated Approval Trial of IFx-2.0 as an Adjunctive Therapy to Keytruda® (Pembrolizumab) in First Line Treatment for Advanced or Metastatic Merkel Cell Carcinoma
TuHURA Biosciences, formed by CohBar and Morphogenesis, a UF startup, has announced the initiation of its Phase 3 accelerated approval trial of IFx-2.0, TuHURA’s lead innate immune agonist, in patients with advanced or metastatic Merkel cell carcinoma (MCC).
LightPath Debuts First Industrial-Grade Cooled Optical Gas Imaging Camera
UF startup LightPath Technologies announced that its subsidiary, G5 Infrared, has launched its first industrial-grade MWIR optical gas imaging camera, following a successful test at a certified facility.
Myosin Therapeutics Receives FDA Clearance To Initiate First-in-Human Trial of MT-125 in Glioblastoma
UF startup Myosin Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s Investigational New Drug (IND) application for MT-125.
Tech Tuesday: University of Florida Startup Is Changing How Students Connect With Classmates
In this week’s Tech Tuesday, UF Innovate host Bethany Gaffey introduces CourseLynx, a UF startup transforming how students connect on campus and in class.
Florida Venture Forum Announces Startups Selected to Present at 2025 Florida Early Stage Venture Conference
Oboro Labs, a UF startup, is among the companies selected to pitch at the 2025 Florida Early Stage Venture Conference, showcasing the innovative technologies emerging from UF’s entrepreneurial ecosystem.
Atsena Therapeutics Announces Positive Clinical Data From Part A of Phase I/II Trial Evaluating ATSN-201 Gene Therapy To Treat X-Linked Retinoschisis (XLRS)
UF startup Atsena Therapeutics announced positive clinical data results from Part A of the LIGHTHOUSE study, a Phase I/II clinical trial evaluating subretinal injection of ATSN-201 for the treatment of X-linked retinoschisis (XLRS).
Oboro Labs and Knowlify Receive ‘Panelists’ Choice’ Awards at GatorPitch
Six University of Florida startups pitched their business plan to more than 100 attendees from Miami’s investor and entrepreneurial community at UF Innovate’s second GatorPitch Miami event on May 8.
Tech Tuesday: University of Florida Startup Aims To Improve How Polymers Are Made
In this week’s Tech Tuesday, UF Innovate host Bethany Gaffey interviews Gregory Kis, CEO of Oboro Labs and winner of the Panelists’ Choice award in the established companies category at the spring GatorPitch Miami event.
Genascence Phase 1b DONATELLO Trial Evaluating Potential First-in-Class Gene Therapy for Knee Osteoarthritis (OA) Meets Primary Endpoint Showing GNSC-001 Was Safe and Well Tolerated Across Multiple Dosing Arms
UF startup Genascence Corporation announced positive 12-month safety and biomarker results from the Phase 1b DONATELLO clinical trial evaluating GNSC-001, a potential first-in-class gene therapy blocking interleukin 1 (IL-1) for the treatment of knee osteoarthritis (OA).